Search Results - "Virgolini, Irene"

Current status of theranostics in prostate cancer by Virgolini, Irene, Decristoforo, Clemens, Haug, Alexander, Fanti, Stefano, Uprimny, Christian

“…The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients…”
Get full text

Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy by Gabriel, Michael, Nilica, Bernhard, Kaiser, Bernhard, Virgolini, Irene J

“…Peptide receptor radionuclide therapy (PRRT) has been used for more than 20 y as a systemic treatment approach in inoperable or metastatic somatostatin…”
Get full text

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review by von Eyben, Finn Edler, Roviello, Giandomenico, Kiljunen, Timo, Uprimny, Christian, Virgolini, Irene, Kairemo, Kalevi, Joensuu, Timo

“…Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment…”
Get full text

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? by Ceci, Francesco, Uprimny, Christian, Nilica, Bernhard, Geraldo, Llanos, Kendler, Dorota, Kroiss, Alexander, Bektic, Jasmin, Horninger, Wolfgang, Lukas, Peter, Decristoforo, Clemens, Castellucci, Paolo, Fanti, Stefano, Virgolini, Irene J

“…To assess the association between PSA levels, PSA kinetics and other factors and a pathological (68)Ga-PSMA PET/CT scan in patients with recurrent prostate…”
Get full text

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer by von Guggenberg, Elisabeth, Uprimny, Christian, Klinger, Maximilian, Warwitz, Boris, Sviridenko, Anna, Bayerschmidt, Steffen, Santo, Gianpaolo di, Virgolini, Irene J

“…PET/CT with the new 68Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68Ga-DOTA-MGS5) was performed on patients with advanced…”
Get full text

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) by Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kulkarni, Harshad R, Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike, Kabasakal, Levent, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene

“…Introduction The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC)…”
Get full text

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer by von Guggenberg, Elisabeth, Uprimny, Christian, Klinger, Maximilian, Warwitz, Boris, Sviridenko, Anna, Bayerschmidt, Steffen, di Santo, Gianpaolo, Virgolini, Irene J

“…PET/CT with the new Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-( -Me)Nle-Asp-1-Nal-NH ( Ga-DOTA-MGS5) was performed on patients with advanced…”
Get full text

[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis by Haubner, Roland, Finkenstedt, Armin, Stegmayr, Armin, Rangger, Christine, Decristoforo, Clemens, Zoller, Heinz, Virgolini, Irene J.

“…Purpose This study was designed to determine safety, tolerability, and radiation burden of a [ 68 Ga]NODAGA-RGD-PET for imaging integrin α v β 3 expression in…”
Get full text

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study by Ahmadzadehfar, Hojjat, Matern, Ralf, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bögemann, Martin, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Svirydenka, Hanna, Sathekge, Mike, Kabasakal, Levent, Yordanova, Anna, Garcia-Perez, Francisco Osvaldo, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene, Rahbar, Kambiz

“…Introduction Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical…”
Get full text

Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use by Hodolic, Marina, Wu, Wen-Yu, Zhao, Zhenyu, Yu, Fei, Virgolini, Irene, Wang, Feng

“…Introduction Over the last decades, multiple peptide receptors were recognized as potential diagnostic and therapeutic targets in nuclear medicine. 68…”
Get full text

[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma by Hutterer, Markus, Nowosielski, Martha, Putzer, Daniel, Jansen, Nathalie L, Seiz, Marcel, Schocke, Michael, McCoy, Mark, Göbel, Georg, la Fougère, Christian, Virgolini, Irene J, Trinka, Eugen, Jacobs, Andreas H, Stockhammer, Günther

“…To assess the sensitivity and specificity of [(18)F]-fluoro-ethyl-l-tyrosine ((18)F-FET) PET in brain tumors and various non-neoplastic neurologic diseases. We…”
Get full text

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma by Hutterer, Markus, Nowosielski, Martha, Putzer, Daniel, Waitz, Dietmar, Tinkhauser, Gerd, Kostron, Herwig, Muigg, Armin, Virgolini, Irene J, Staffen, Wolfgang, Trinka, Eugen, Gotwald, Thaddäus, Jacobs, Andreas H, Stockhammer, Guenther

“…The objective of this study was to compare MRI response assessment with metabolic O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET response evaluation during…”
Get full text

High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma by Jha, Abhishek, Taïeb, David, Carrasquillo, Jorge A., Pryma, Daniel A., Patel, Mayank, Millo, Corina, de Herder, Wouter W., Del Rivero, Jaydira, Crona, Joakim, Shulkin, Barry L., Virgolini, Irene, Chen, Alice P., Mittal, Bhagwant R., Basu, Sandip, Dillon, Joseph S., Hope, Thomas A., Mari Aparici, Carina, Iagaru, Andrei H., Hicks, Rodney J., Avram, Anca M., Strosberg, Jonathan R., Civelek, Ali Cahid, Lin, Frank I., Pandit-Taskar, Neeta, Pacak, Karel

“…Abstract Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG) and peptide receptor radionuclide therapy (177Lu or 90Y)…”
Get full text

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis by von Eyben, Finn Edler, Bauman, Glenn, von Eyben, Rie, Rahbar, Kambiz, Soydal, Cigdem, Haug, Alexander R, Virgolini, Irene, Kulkarni, Harshad, Baum, Richard, Paganelli, Giovanni

“…The aim of the review was to evaluate patient and treatment characteristics for patients with metastatic castration-resistant prostate cancer (mCRPC) treated…”
Get full text

Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease by SCHERFLER, Christoph, SEPPI, Klaus, MAIR, Katherina J, DONNEMILLER, Eveline, VIRGOLINI, Irene, WENNING, Gregor K, POEWE, Werner

“…The aim of this study was to investigate the distribution and the degree of asymmetric putaminal dopamine transporter availability in right-handed patients…”
Get full text

(68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient by Uprimny, Christian, Kroiss, Alexander, Nilica, Bernhard, Buxbaum, Sabine, Decristoforo, Clemens, Horninger, Wolfgang, Virgolini, Irene J

Get full text

On the Way for Patients with Prostate Cancer to the Best Use of PSMA by von Eyben, Finn Edler, Bauman, Glenn, Kapp, Daniel S, Virgolini, Irene, Paganelli, Giovanni

“…In recent years, the prostate-specific membrane antigen (PSMA) has achieved a significant role in the diagnostics and treatments of patients with prostate…”
Get full text

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review by Heidegger, Isabel, Kesch, Claudia, Kretschmer, Alexander, Tsaur, Igor, Ceci, Francesco, Valerio, Massimo, Tilki, Derya, Marra, Giancarlo, Preisser, Felix, Fankhauser, Christian D., Zattoni, Fabio, Chiu, Peter, Puche-Sanz, Ignacio, Olivier, Jonathan, van den Bergh, Roderik C. N., Kasivisvanathan, Veeru, Pircher, Andreas, Virgolini, Irene, Gandaglia, Giorgio

“…Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant…”
Get full text

Automated Production of [ 68 Ga]Ga-Desferrioxamine B on Two Different Synthesis Platforms by Kraihammer, Martin, Petřík, Miloš, Rangger, Christine, Gabriel, Michael, Haas, Hubertus, Nilica, Bernhard, Virgolini, Irene, Decristoforo, Clemens

“…PET imaging of bacterial infection could potentially provide added benefits for patient care through non-invasive means. [ Ga]Ga-desferrioxamine B-a…”
Get full text

Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a retrospective study by Kapelari, Klaus, Kirchlechner, Christine, Högler, Wolfgang, Schweitzer, Katharina, Virgolini, Irene, Moncayo, Roy

“…Age- and sex-specific reference intervals are an important prerequisite for interpreting thyroid hormone measurements in children. However, only few studies…”
Get full text